Avanafil

• CAT Number: A000366
• CAS Number: 330784-47-9
• Molecular Formula: C23H26ClN7O3
• Molecular Weight: 483.95
• Purity: ≥95%
• Target: PDE
• Solubility: >17.6mg/mL in DMSO
• Storage: -20°C
• InChI: 1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1
• InChIKey: WEAJZXNPAWBCOA-INIZCTEOSA-N
• SMILES: COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCCC4CO)Cl

Avanafil (Cat. No: A000366) is a highly selective oral phosphodiesterase 5 inhibitor. Phase I, II and III clinical trials showed that compared with another phosphodiesterase 5 inhibitors, avanafil has the characteristics of rapid onset, short duration of action, less adverse reactions, and good clinical efficacy and safety in the treatment of erectile dysfunction.

Reference

1: Berges R, Schremmer D, Limberg R. [Avanafil for the treatment of erectile
dysfunction in practice. Non-interventional study AVANTI]. MMW Fortschr Med. 2017
Jun;159(Suppl 5):16-21. doi: 10.1007/s15006-017-9804-1. Epub 2017 Jun 22. German.
PubMed PMID: 28643292.

2: Park HJ, Kim SW, Kim JJ, Lee SW, Paick JS, Ahn TY, Park K, Park JK, Park NC. A
Randomized, Placebo-Controlled, Double-Blind, Multi-Center Therapeutic
Confirmatory Study to Evaluate the Safety and Efficacy of Avanafil in Korean
Patients with Erectile Dysfunction. J Korean Med Sci. 2017 Jun;32(6):1016-1023.
doi: 10.3346/jkms.2017.32.6.1016. PubMed PMID: 28480661; PubMed Central PMCID:
PMC5426242.

3: Soliman KA, Ibrahim HK, Ghorab MM. Effects of different combinations of
nanocrystallization technologies on avanafil nanoparticles: in vitro, in vivo and
stability evaluation. Int J Pharm. 2017 Jan 30;517(1-2):148-156. doi:
10.1016/j.ijpharm.2016.12.012. Epub 2016 Dec 7. PubMed PMID: 27939570.

4: Soliman KA, Ibrahim HK, Ghorab MM. Formulation of avanafil in a solid
self-nanoemulsifying drug delivery system for enhanced oral delivery. Eur J Pharm
Sci. 2016 Oct 10;93:447-55. doi: 10.1016/j.ejps.2016.08.050. Epub 2016 Aug 31.
PubMed PMID: 27590128.

5: Soliman KA, Ibrahim HK, Ghorab MM. Effect of different polymers on
avanafil-β-cyclodextrin inclusion complex: in vitro and in vivo evaluation. Int J
Pharm. 2016 Oct 15;512(1):168-177. doi: 10.1016/j.ijpharm.2016.08.044. Epub 2016
Aug 27. PubMed PMID: 27576665.

6: Zurawin JL, Stewart CA, Anaissie JE, Yafi FA, Hellstrom WJ. Avanafil for the
treatment of erectile dysfunction. Expert Rev Clin Pharmacol. 2016
Sep;9(9):1163-70. doi: 10.1080/17512433.2016.1212655. Epub 2016 Aug 2. Review.
PubMed PMID: 27416913.

7: Mirone V, Fusco F, Parazzini F, Zucchi A. A survey on the experience of 136
Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors
and recommendations for the use of Avanafil in the clinical practice. Arch Ital
Urol Androl. 2016 Jul 4;88(2):128-32. doi: 10.4081/aiua.2016.2.128. PubMed PMID:
27377089.

8: Boeri L, Capogrosso P, Ventimiglia E, Serino A, La Croce G, Russo A, Damiano
R, Montorsi F, Salonia A. Avanafil – a further step to tailoring patient needs
and expectations. Expert Rev Clin Pharmacol. 2016 Sep;9(9):1171-81. doi:
10.1080/17512433.2016.1195261. Epub 2016 Jun 13. Review. PubMed PMID: 27232892.

9: Multivariate Approaches for Simultaneous Determination of Avanafil and
Dapoxetine by UV Chemometrics and HPLC-QbD in Binary Mixtures and Pharmaceutical
Product. J AOAC Int. 2016 Apr 7. [Epub ahead of print] PubMed PMID: 27075270.

10: Kurakula M, Ahmed OA, Fahmy UA, Ahmed TA. Solid lipid nanoparticles for
transdermal delivery of avanafil: optimization, formulation, in-vitro and ex-vivo
studies. J Liposome Res. 2016 Dec;26(4):288-96. doi:
10.3109/08982104.2015.1117490. Epub 2016 Jan 19. PubMed PMID: 26784833.